Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Hematology Oncology Consultants Inc, Columbus, Ohio, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Vermont Cancer Center, Burlington, Vermont, United States
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
St. Vincent Hospital and Health Center, Billings, Montana, United States
Mayo Clinic, Jacksonville, Florida, United States
Hopital Saint-Louis, Paris, France
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
Centre Hospital Regional Universitaire de Limoges, Limoges, France
Hopital Saint Antoine, Paris, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.